AR062928A1 - Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 - Google Patents
Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2Info
- Publication number
- AR062928A1 AR062928A1 ARP070104169A ARP070104169A AR062928A1 AR 062928 A1 AR062928 A1 AR 062928A1 AR P070104169 A ARP070104169 A AR P070104169A AR P070104169 A ARP070104169 A AR P070104169A AR 062928 A1 AR062928 A1 AR 062928A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- methyl
- cycloalkyl
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 title abstract 2
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 17
- 239000001257 hydrogen Substances 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- -1 -CONR13R14 Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0618776A GB0618776D0 (en) | 2006-09-22 | 2006-09-22 | Novel compounds |
| GB0704012A GB0704012D0 (en) | 2007-03-01 | 2007-03-01 | Novel compounds |
| GB0717170A GB0717170D0 (en) | 2007-09-04 | 2007-09-04 | Novelcompounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062928A1 true AR062928A1 (es) | 2008-12-17 |
Family
ID=39092148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104169A AR062928A1 (es) | 2006-09-22 | 2007-09-20 | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20080146606A1 (enExample) |
| EP (1) | EP2069341B1 (enExample) |
| JP (1) | JP2010504301A (enExample) |
| AR (1) | AR062928A1 (enExample) |
| AT (1) | ATE493411T1 (enExample) |
| CL (1) | CL2007002708A1 (enExample) |
| DE (1) | DE602007011645D1 (enExample) |
| PE (1) | PE20080925A1 (enExample) |
| TW (1) | TW200836724A (enExample) |
| UY (1) | UY30600A1 (enExample) |
| WO (1) | WO2008034860A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
| TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| GB0804592D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
| GB0804591D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
| US8642069B2 (en) * | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2717694A4 (en) * | 2011-06-10 | 2014-11-12 | Glaxosmithkline Intellectual Property Ltd | NEW COMPOUNDS |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9796708B2 (en) * | 2013-03-14 | 2017-10-24 | Abbvie Inc. | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors |
| US9073922B2 (en) * | 2013-03-14 | 2015-07-07 | Abbvie, Inc. | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN114210133B (zh) * | 2021-12-13 | 2023-01-24 | 广德辉龙环保科技有限公司 | 一种抗紫外线过滤袋及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04002070A (es) * | 2001-09-19 | 2004-06-07 | Pharmacia Corp | Compuestos de indazol sustituidos para el tratamiento de la inflamacion. |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
-
2007
- 2007-09-20 US US11/858,143 patent/US20080146606A1/en not_active Abandoned
- 2007-09-20 DE DE602007011645T patent/DE602007011645D1/de active Active
- 2007-09-20 AR ARP070104169A patent/AR062928A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135178A patent/TW200836724A/zh unknown
- 2007-09-20 AT AT07820377T patent/ATE493411T1/de not_active IP Right Cessation
- 2007-09-20 US US12/442,012 patent/US20100035917A1/en not_active Abandoned
- 2007-09-20 CL CL200702708A patent/CL2007002708A1/es unknown
- 2007-09-20 US US11/858,144 patent/US20080176891A1/en not_active Abandoned
- 2007-09-20 PE PE2007001270A patent/PE20080925A1/es not_active Application Discontinuation
- 2007-09-20 EP EP07820377A patent/EP2069341B1/en active Active
- 2007-09-20 JP JP2009528719A patent/JP2010504301A/ja active Pending
- 2007-09-20 UY UY30600A patent/UY30600A1/es unknown
- 2007-09-20 WO PCT/EP2007/059933 patent/WO2008034860A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2069341A1 (en) | 2009-06-17 |
| PE20080925A1 (es) | 2008-09-04 |
| US20080176891A1 (en) | 2008-07-24 |
| US20100035917A1 (en) | 2010-02-11 |
| US20080146606A1 (en) | 2008-06-19 |
| DE602007011645D1 (de) | 2011-02-10 |
| JP2010504301A (ja) | 2010-02-12 |
| EP2069341B1 (en) | 2010-12-29 |
| WO2008034860A1 (en) | 2008-03-27 |
| ATE493411T1 (de) | 2011-01-15 |
| UY30600A1 (es) | 2008-05-02 |
| CL2007002708A1 (es) | 2008-04-04 |
| TW200836724A (en) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR113895A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| PE20040373A1 (es) | Composiciones herbicidas que comprenden derivados de isoxazolina | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR061974A1 (es) | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| AR069304A1 (es) | Inhibidores del transportador equilibrativo de nucleosidos ent1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |